In patients who do not respond to this therapy, it has been demonstrated that the tumour cells carried one of the mutations of the KRAS gene, which is found located on the EGFR gene pathway, which caused the activation of this pathway independently of the EGFR blocking [143]. Here, KRAS is linked to neoplasm.